Characterization of the Genomic and Immunologic Diversity of Malignant Brain Tumors through Multisector Analysis

Multisector analysis of malignant brain tumors highlights substantial differences in immunogenomic landscapes, with gliomas harboring greater spatial heterogeneity at a genomic, neoantigen, and T-cell repertoire level.

[1]  Voichita D. Marinescu,et al.  Whole-genome sequencing of glioblastoma reveals enrichment of non-coding constraint mutations in known and novel genes , 2020, Genome Biology.

[2]  Angela E. Leek,et al.  Publisher Correction: Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer , 2020, Nature Medicine.

[3]  Nicholas L. Bormann,et al.  A transcriptomic map of murine and human alopecia areata. , 2020, JCI insight.

[4]  C. Brennan,et al.  Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells , 2020, Cell.

[5]  B. Becher,et al.  Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific Instruction of Tissue-Invading Leukocytes , 2020, Cell.

[6]  Raymond Y Huang,et al.  Mechanisms and therapeutic implications of hypermutation in gliomas , 2020, Nature.

[7]  Nicholas D. Camarda,et al.  Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma , 2020, Nature Genetics.

[8]  Howard Y. Chang,et al.  CRISPR-engineered T cells in patients with refractory cancer , 2020, Science.

[9]  F. Jamali,et al.  Single dose pharmacokinetics and bioavailability of glucosamine in the rat. , 2002, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[10]  Malachi Griffith,et al.  pVACtools: A Computational Toolkit to Identify and Visualize Cancer Neoantigens , 2020, Cancer Immunology Research.

[11]  Martin L. Miller,et al.  Unraveling Tumor-Immune Heterogeneity in Advanced Ovarian Cancer Uncovers Immunogenic Effect of Chemotherapy , 2018, bioRxiv.

[12]  Nicholas L. Bormann,et al.  scRepertoire: An R-based toolkit for single-cell immune receptor analysis. , 2020, F1000Research.

[13]  Malachi Griffith,et al.  Best practices for bioinformatic characterization of neoantigens for clinical utility , 2019, Genome Medicine.

[14]  Steven L Salzberg,et al.  Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype , 2019, Nature Biotechnology.

[15]  Davide Prandi,et al.  TPES: tumor purity estimation from SNVs , 2019, Bioinform..

[16]  Y. Kluger,et al.  Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Castle,et al.  Actively personalized vaccination trial for newly diagnosed glioblastoma , 2018, Nature.

[18]  Alyssa R. Richman,et al.  Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial , 2018, Nature.

[19]  P. A. Futreal,et al.  Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer , 2018, Nature Communications.

[20]  Christoph Hafemeister,et al.  Comprehensive integration of single cell data , 2018, bioRxiv.

[21]  Jill S Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. , 2018, Neuro-oncology.

[22]  Susan M. Chang,et al.  Temozolomide-associated hypermutation in gliomas. , 2018, Neuro-oncology.

[23]  Ji-Yong Um,et al.  Human glioblastoma arises from subventricular zone cells with low-level driver mutations , 2018, Nature.

[24]  G. Getz,et al.  Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors , 2018, Nature Genetics.

[25]  K. Ligon,et al.  Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143 , 2018, Neuro-oncology.

[26]  Christopher A. Miller,et al.  Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastoma , 2018, Neuro-oncology.

[27]  D. Bigner,et al.  T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma , 2018, Clinical Cancer Research.

[28]  A. Kriegstein,et al.  Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment , 2017, Genome Biology.

[29]  C. Maher,et al.  ClonEvol: clonal ordering and visualization in cancer sequencing , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  Ryan Emerson,et al.  TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. , 2017, Cancer discovery.

[31]  S. Rosenberg,et al.  Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  K. Mansfield,et al.  A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma , 2017, Science Translational Medicine.

[33]  Nicolai J. Birkbak,et al.  Tracking the Evolution of Non‐Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[34]  Patrick Danaher,et al.  Gene expression markers of Tumor Infiltrating Leukocytes , 2016, Journal of Immunotherapy for Cancer.

[35]  Grace X. Y. Zheng,et al.  Massively parallel digital transcriptional profiling of single cells , 2016, Nature Communications.

[36]  Lior Pachter,et al.  Differential analysis of RNA-seq incorporating quantification uncertainty , 2016, Nature Methods.

[37]  L. Recht,et al.  Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. , 2017, The Lancet. Oncology.

[38]  Christopher A. Miller,et al.  Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy. , 2016, Cancer discovery.

[39]  D. Merico,et al.  Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  A. Vortmeyer,et al.  Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[41]  F. Cunningham,et al.  The Ensembl Variant Effect Predictor , 2016, Genome Biology.

[42]  Yufeng Shen,et al.  Diversity and divergence of the glioma-infiltrating T-cell receptor repertoire , 2016, Proceedings of the National Academy of Sciences.

[43]  N. Rosenfeld,et al.  The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes , 2016, Nature Communications.

[44]  Eric Talevich,et al.  CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing , 2016, PLoS Comput. Biol..

[45]  Nicolai J. Birkbak,et al.  Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.

[46]  Ginu A. Thomas,et al.  Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. , 2016, JCI insight.

[47]  E. Mardis,et al.  pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens , 2016, Genome Medicine.

[48]  Hanlee P. Ji,et al.  Pan-cancer analysis of the extent and consequences of intratumor heterogeneity , 2015, Nature Medicine.

[49]  S. Gabriel,et al.  Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.

[50]  Robert T. Jones,et al.  Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. , 2015, Cancer discovery.

[51]  Obi L. Griffith,et al.  Genome Modeling System: A Knowledge Management Platform for Genomics , 2015, PLoS Comput. Biol..

[52]  B. Vogelstein,et al.  PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  J. Bading,et al.  Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma , 2015, Clinical Cancer Research.

[54]  Ash A. Alizadeh,et al.  Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.

[55]  K. Hemminki,et al.  TERT promoter mutations and telomere length in adult malignant gliomas and recurrences , 2015, Oncotarget.

[56]  Jill S Barnholtz-Sloan,et al.  Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution , 2015, Genome research.

[57]  Eric C Leuthardt,et al.  Molecular and cellular heterogeneity: the hallmark of glioblastoma. , 2014, Neurosurgical focus.

[58]  Yu Cao,et al.  Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing , 2014, Science.

[59]  Roland Eils,et al.  circlize implements and enhances circular visualization in R , 2014, Bioinform..

[60]  Obi L. Griffith,et al.  SciClone: Inferring Clonal Architecture and Tracking the Spatial and Temporal Patterns of Tumor Evolution , 2014, PLoS Comput. Biol..

[61]  K. Cornetta,et al.  Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma , 2014, Clinical Cancer Research.

[62]  Steven J. M. Jones,et al.  Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma , 2014, Science.

[63]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[64]  Heng Li.  Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM , 2013, 1303.3997.

[65]  V. P. Collins,et al.  Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics , 2013, Proceedings of the National Academy of Sciences.

[66]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[67]  K. Yura,et al.  CoDP: predicting the impact of unclassified genetic variants in MSH6 by the combination of different properties of the protein , 2013, Journal of Biomedical Science.

[68]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[69]  Wendy S. W. Wong,et al.  Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs , 2012, Bioinform..

[70]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[71]  Christopher A. Miller,et al.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.

[72]  G. Getz,et al.  GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.

[73]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[74]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[75]  Kai Ye,et al.  Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads , 2009, Bioinform..

[76]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[77]  Mimi Y. Kim,et al.  Dominant effects of an Msh6 missense mutation on DNA repair and cancer susceptibility. , 2004, Cancer cell.

[78]  Piero Carninci,et al.  CTAB-urea method purifies RNA from melanin for cDNA microarray analysis. , 2004, Pigment cell research.

[79]  A. Twijnstra,et al.  Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma , 2002, Cancer.

[80]  H. Hollema,et al.  Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. , 2002, American journal of human genetics.

[81]  L. Eckhart,et al.  Melanin binds reversibly to thermostable DNA polymerase and inhibits its activity. , 2000, Biochemical and biophysical research communications.